California, Minnesota, & Ohio
The KAN-101-02 Study is a phase 1b/2 clinical trial testing the safety and tolerability of the investigational medication KAN-101.
KAN-101 targets the immune cells that drive celiac disease and leaves the otherwise healthy components of the immune system intact. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens.
- 18-70 years
- Biopsy-confirmed celiac disease
- On gluten-free diet for at least the last 12 months
Learn more at clinicaltrials.gov/ct2/show/NCT05574010